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Abstract 
Background 
Codeine misuse and dependence poses a clinical and public health challenge. However, little is 
known about dependence and treatment needs in the UK and Ireland. 
Aim 
To characterise codeine use, dependence, and help-seeking behaviour. 
Design 
An online cross-sectional survey advertised on Facebook, Twitter, health and drug websites and 
e-mail circulars. 
Methods 
The survey collected data on demographics and codeine use amongst adults from the UK and 
Ireland. The Severity of Dependence Scale measured the level of codeine dependence.  
Results 
The sample of 316 respondents had a mean age of 35.3 years (SD = 12.3) and 67% were 
women. Of the 316 respondents, 54 scored ≥5 on the Severity of Dependence Scale indicating 
codeine dependence (17.1%). Our study found that codeine dependence is a problem with both 
prescribed and ‘over-the-counter’ codeine. Codeine dependence was associated with daily use 
of codeine, faking or exaggerating symptoms to get a prescription for codeine and ‘pharmacy 
shopping’ (P < 0.01). A higher number of respondents had sought advice on the Internet (12%) 
rather than from their general medical practitioner (GP) (5.4%). Less than 1% of respondents 
had sought advice from a pharmacist. 
Conclusions 
Codeine dependent users were more likely to seek help on the Internet to control their use of 
codeine than from a GP, which may indicate a potential for greater specialised addiction 
treatment demand through increased identification and referrals in primary care. 
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Introduction 
Opioid analgesics are widely used and associated with misuse and dependence in the UK and 
Ireland.1-4 The use of opioid analgesics increased from around 35.9m Defined Daily Doses (DDD) 
in 2001-03 to 117.9m DDD in 2011-13 in the UK and from roughly 3.1m DDD to 9.3m DDD in 
Ireland.5 During this period, the global consumption of codeine grew from 183 tons in 1995 to 
287 tons in 2014, making it one of the most commonly used opioids in both these countries.6 
 However, comparing statistics of codeine use with data on codeine addiction and 
mortality indicates a problem. In the UK, 2.2% of those attending specialist addiction treatment 
did so for codeine (2013/14).7 This amounts to over 4,000 people and has steadily increased 
over time. In Ireland, 1.7% (1,382 people) attended drug treatment for codeine between 2008 
to 2012.8 Combined codeine and morphine mortality data from Ireland shows death-rates have 
remained stable over the past five years with 58 deaths in 2010 and 61 deaths in 2014.9 
However, data from England and Wales recorded 88 deaths relating to codeine in 2011 rising to 
128 deaths in 2015.10 Codeine or a codeine containing compound were implicated in 31 deaths 
in Scotland in 2015, presenting an increase over the last decade.11 
 The control of codeine is similar in the UK and Ireland, reflecting a similar judgement of 
safety issues. In both countries, codeine is available as Prescription-only medicines (POM) and 
as Pharmacy medicines (P) sold ‘over-the-counter’ in licensed pharmacies without a medical 
prescription.12 Prescribed codeine may contain a high dose of codeine (15, 30 or 60 mg per unit 
dose), either alone or in combination with a non-opioid analgesic, such as paracetamol or 
ibuprofen. The codeine dose in ‘over-the-counter’ preparations is restricted to lower amounts 
(maximum 12.8 mg per unit dose). 
 Studies from the UK and Ireland have examined the use of ‘over-the-counter’ codeine 
specifically,13,14 with few addressing the potential for misuse and dependence of high-strength 
prescription-only codeine. However, a UK survey of general medical practitioners (GPs) 
underlined problems relating to both categories: more than half reported that patients lack 
awareness of the potential harms of prescribed codeine and more than 80% reported that the 
availability of ‘over-the-counter’ codeine adds to the potential for misuse.15 An investigation of 
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codeine use and dependence in the UK and Ireland is timely because of the recent indicators of 
problems of mortality and dependence. 
 This study aims to characterise codeine use and dependence in an online sample of 
people from the UK and Ireland. It utilises a cross-sectional dataset from an online survey to 
investigate use, severity of dependence, ‘shopping’ behaviours and utilisation of support 
resources to manage codeine use relating to prescription-only and ‘over-the-counter’ codeine. 
These factors mark potential problematic health issues and treatment needs arising from 
codeine dependence important to development of practice and policy. 
Methods 
Self-reported data about codeine use amongst adults (≧ 18 years) residing in the UK or Ireland 
were collected from an online survey. Ethical approval was granted by the Psychiatry, Nursing, 
and Midwifery Research Ethics Subcommittee (PNM RESC), King’s College London. REC 
Reference Number: PNM/14/15-110. 
Recruitment 
A link to the survey was posted via Facebook, Twitter, discussion forums, newsletters, and e-
mail circulars, namely from (i) websites dedicated to health, pain and medicine use; (ii) drug 
addiction organisations; (iii) an online drug discussion forum, where users share their 
experiences of drug use;16,17 (iv) e-mail circulars to staff and students at two universities to 
include young people. The main inclusion criteria for the study was use of medicines containing 
codeine (prescribed and non-prescribed) in the last three months. Participation was anonymous 
and uncompensated. 
Measurements 
The questionnaire contained 49 questions covering respondents’ demographics, codeine use, 
dependence, and help-seeking (See supplementary information). Respondents were asked to 
write in the amount of codeine (mg) taken in a day on the last occasion of use. Instructions on 
calculating the dose was provided. Use of codeine was collapsed into two categories, under and 
over the recommended daily dose of 240 mg codeine under the guidelines of British National 
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Formulary (BNF).18 Importantly, other restrictions of consumption exist with combination 
tablets containing codeine and ibuprofen (BNF maximum daily dose = 2,000 mg ibuprofen) or 
paracetamol (BNF maximum daily dose = 4,000 mg paracetamol). However, given this present 
study was primarily concerned with codeine dependence, the maximum codeine dose was 
investigated. Frequency of use was measured over the last three months in terms non-daily and 
daily use. 
 Respondents were asked to identify their main source of codeine. They were asked to 
choose between: (i) prescribed by a professional; (ii) ‘over-the-counter’ in a pharmacy; (iii) shop 
on the Internet; (iv) from family, partner, friend or acquaintance. 
 The Severity of Dependence Scale was used to assess dependence. The Scale is short 
and easy to understand, allowing people to answer it quickly and consistently.19 It consists of 
five questions, scored from 0 to 3, and can be used to measure the degree of dependence on a 
range of substances,19,20 including medicines.21 We used a cut-off score of ≥5 as this has 
previously been used to determine codeine dependence.22 Respondents answered all the 
required scale items. 
 Questions from a scale designed to measure reasons for substance use were included to 
investigate use and misuse of codeine.23 
 Additional questions asked about codeine ‘shopping’ of both prescribed and ‘over-the-
counter’ codeine using a definition of obtaining a prescription for codeine from three or more 
prescribers over a period of six months and obtaining ‘over-the-counter’ codeine from three or 
more pharmacists over a six-month period.24 
 Help-seeking to control codeine use was captured in three questions, asking 
respondents to indicate if they had sought advice to help control their use of codeine from a (i) 
pharmacist, (ii) GP, and (iii) on the Internet. 
 The questionnaire was designed in Bristol Online Surveys (BOS), revised by an expert 
advisory group to the study, and reviewed by substance misuse treatment providers and 
service users with codeine misuse experience to ensure its appropriateness regarding clarity of 
instructions, questions, and format. 
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Statistical analysis 
Data were downloaded from BOS and entered into SPSS version 21. Descriptive statistics were 
used to describe demographics, codeine use patterns, ‘shopping’ behaviours and help-seeking 
using frequencies and mean scores. Binary logistic regression was used to examine the 
association between independent variables and codeine dependence. Comparisons were made 
between those who were not dependent and those who were. The independent variables were 
demographic characteristics, codeine use (including main source of codeine, frequency of use, 
dose and reasons for use), codeine ‘shopping’ behaviours and sources for help-seeking to 
control the use of codeine. 
Results 
Between July 2015 and March 2016, 316 respondents completed the survey. The mean age of 
the sample was 35.3 years (SD = 12.3) and 67% were women. Over half of the sample were 
employed, either full (46.2%) or part-time (14.2%). The remainder of the respondents received 
student allowance (13.9%), disability allowance (6.0%), temporary benefits (2.8%) or pension 
(2.2%). In the sample, 3.2% reported no income. A majority were residents in the UK (90.5%); 
9.5% were residing in Ireland. 
 The main sources of codeine were evenly split between ‘over-the-counter’ products 
purchased in a pharmacy (43.7%) and prescription codeine (43.4%). About one in twelve (7.9%) 
reported obtaining codeine through a family member, friend or acquaintance as their main 
source of codeine. A shop on the Internet was the main supply source for 3.2% of the 
respondents. 
  Most respondents took less than 240 mg codeine over a daily period (74.7%) and only 
9.8% took more. However, 15.5% were unable to provide their daily consumption levels. A third 
of the respondents were daily users of codeine (36.7%). 
Demographics and codeine dependence 
Of the 316 respondents, 54 scored ≥5 on the Severity of Dependence Scale indicating codeine 
dependence (17.1%). During the last 3 months, 13.3% indicated tolerance to codeine on a 
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weekly basis; 8.5% indicated withdrawal; and 5.7% indicated both. The mean age of codeine 
dependent users (38.7 years; SD = 11.1) was significantly higher than the mean age of non-
dependent users (34.7 years; SD = 12.5) (P < 0.01). Those who were dependent on codeine 
were more likely to be between 41 to 50 years old and less likely to be 30 years old and under, 
in comparison with those who were not dependent (Table 1). No significant differences were 
found for other demographic factors. 
Codeine consumption and risk behaviour 
Table 1 shows codeine consumption according to non-dependence and dependence. A higher 
proportion of codeine dependent users reported prescription codeine as their main source of 
codeine than non-dependent users. Dependent users were less likely to report ‘over-the-
counter’ codeine as their main source of codeine compared to those who were not dependent. 
In relation to codeine consumption, there was a significantly higher proportion of codeine 
dependent users who were daily users of codeine, in comparison with non-dependent users. 
Reasons for codeine use 
Many used codeine for genuine medical reasons, namely for treatment of pain. However, those 
who were dependent upon codeine were less likely to have used codeine for pain treatment 
and more likely to have used codeine to help relax, to stop worrying about a problem, and to 
ease withdrawal symptoms of other opioids, compared to those who were not dependent. 
Codeine ‘Shopping’ 
Faking and exaggerating symptoms to get a prescription for codeine was indicated by 14.1% 
respondents, presenting the most frequent ‘shopping’ behaviour for prescribed codeine. This 
was followed by receiving prescriptions from three or more prescribers in six months (14%). 
The most common ‘shopping’ behaviour for ‘over-the-counter’ codeine was obtaining codeine 
from three or more pharmacies over a six-month period (35.8%). The least common was being 
refused a sale of ‘over-the-counter’ codeine in a pharmacy and then buying from the Internet 
(2.2%). ‘Shopping’ behaviours for prescribed and ‘over-the-counter’ codeine were significant in 
predicting an association with codeine dependence (Table 3). 
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Help-seeking to manage codeine use 
Finally, table 4 shows that codeine dependent users were more likely to have sought help to 
manage codeine use on the Internet than non-dependent users. Overall, a higher proportion of 
respondents had sought advice on the Internet (12%) than from a GP/family doctor (5.4%). Less 
than 1% had sought advice from a pharmacist. Out of the full sample, eight (2.5%) had received 
specialised addiction treatment for codeine dependence. 
Discussion 
To our knowledge, this is the first study to use an online design to recruit a sample of codeine 
dependent users in the UK and Ireland. The results show that a third of the respondents were 
daily users of codeine, 9.8% took more than 240 mg codeine on their last occasion of use and 
17.1% screened positive for codeine dependence. This compares favourably with an online 
survey of 800 ‘over-the-counter’ codeine users from Australia where 17.3% screened positive 
for dependence.22 The mean age of codeine dependent users was significantly higher than the 
mean age of non-dependent users. Most had sought help to manage their codeine use on the 
Internet (12%). Only 5.4% sought advice from a doctor and less than 1% from a community 
pharmacy. The group of respondents were of a relatively young age and active Internet users. 
This may be one of the explanations for the high use of Internet-based help-resources. 
Importantly, our study found that codeine dependence is an issue with both prescription-only 
and ‘over-the-counter’ codeine. 
 Amongst those who were codeine dependent users, a higher proportion reported 
prescribed codeine as the main source of codeine, in comparison to non-dependent users. This 
may be explained by the higher potency of prescribed codeine formulations and highlights the 
need for GP monitoring of patients prescribed codeine on a long-term basis. The Royal College 
of General Practitioners (UK) has published fact sheets,25 offering advice on what can be a 
difficult conversation with patients who would benefit from a change in their use of opioids.26  
 Approximately one in ten exceeded the recommended 24-hours dose of codeine on the 
last occasion of use. Considering the high and frequent dosages recorded in our study, some 
patients may benefit from more regular consultations over a period allowing for dose tapering 
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to prevent withdrawal.27 Further caution is needed in those using codeine combination 
medicines where high and repeated doses of paracetamol or ibuprofen can result in serious 
harm, such as gastrointestinal haemorrhage, ulcers and renal failure.28 
 In comparison with dependent users, a higher proportion of non-dependent users took 
codeine for treatment of pain which is indicated in the accepted medical guidance for the use 
of this drug. However, we found that dependent users were more likely than non-dependent 
users to take codeine to help with anxiety and depression. Previous research suggests that 
codeine administration for emotional distress may be a good indicator for dependence or risk 
of developing dependence.29 GPs and pharmacists need to be vigilant of reasons for use when 
deciding to prescribe or sell codeine. 
 About one in four had been refused codeine in a pharmacy and gone to a different 
pharmacy to obtain codeine. In contrast with these results, a qualitative study from the UK 
found that users of ‘over-the-counter’ codeine generally reported few episodes of being 
challenged by a pharmacist.30 A possible explanation is the high and frequent dosages recorded 
in our study, which may have made it easier for pharmacists to identify inappropriate use. This 
finding highlights that restrictive dispensing policies and engagement between pharmacy 
customers and staff could potentially reduce excessive codeine use. 
 Help to regain control over the use of codeine was less likely to be sought from GPs and 
pharmacists than from sources on the Internet. This is consistent with findings from previous 
research in the UK where pharmacists were not referred to at all when seeking help to deal 
with codeine dependence.30 But a shift in the role of pharmacies in providing a more 
comprehensive health service to the community has been shown to be beneficial.31 Alongside 
increased identification, treatment and referral of harmful codeine use and dependence in 
General Practice, screening and brief interventions delivered by community pharmacies could 
offer immediate support to individuals with codeine misuse experience and help local areas 
address problematic opioid use. 
 Use of the Internet for information on managing medicine addictions is not surprising 
given the anonymity and convenience offered. However, our findings underline the potential 
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for greater demand for treatment of codeine dependence if a greater number of codeine 
dependent users seeking help online were identified in primary care and referred to specialist 
help. 
Limitations 
The majority of questions in the online questionnaire were mandatory and had to be answered 
before respondents could continue to the next and missing data was therefore uncommon. 
However, a considerable amount of missing data on the respondents’ use of codeine on the last 
occasion of use precluded us from analysing consumption according to non-dependence and 
dependence. 
Several limitations of online recruitment should be considered. First, the anonymity 
offered by many forms of online participation means there are unknown characteristics of 
respondents. Second, in an online environment, respondents are not always precisely bounded 
by activity or geography.32 As such, there is not always a specific population to draw a 
representative sample from, restricting the ability to confirm an accurate response rate. Third, 
in our and other online studies, there may have been potential for selection in favour of 
younger, better educated and more technologically knowledgeable people. In contrast, an 
online survey potentially excludes more vulnerable people with no immediate access to the 
Internet, including those with unstable housing situation and people in prison. Fourth, other 
characteristics of online communities may include dishonesty or false replies due to lack of 
accountability, compared to face to face engagement of research participants. Despite these 
limitations this and similar online research studies22 are important initial investigations of 
codeine use and dependence. The strength lies in providing information about under-
researched populations of codeine dependent users in the UK and Ireland. 
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Tables 
 
Table 1. Demographics and codeine use. 
 Respondents scoring <5 on the 
Severity of Dependence Scale 
(not indicating codeine 
dependence) 
(N = 262) 
Respondents scoring ≧5 on the 
Severity of Dependence Scale 
(indicating codeine 
dependence) 
(N = 54) 
 
 % % OR (95% CI) 
Demographics    
Age (30 and under) 47 28** 0.44 (0.23−0.84) 
Age (31 - 40) 23 28 1.32 (0.68−2.57) 
Age (41 - 50) 18 37** 2.69 (1.42−5.08) 
Age (51 - 60) 10 4✝ ✝ 
Age (61 and over) 3 4✝ ✝ 
Female 68 67 0.98 (0.52−1.85) 
Residents UK 90 94 1.01 (0.99−1.02) 
Main source of codeine    
Prescribed by a professional 42 50 1.38 (0.77−2.49) 
Over-the-counter’ from a 
pharmacy (no prescription) 
46 32* 0.54 (0.29−1) 
Codeine consumption    
Daily use in last 3 months 25 94** 51.52 (15.56−170.66) 
* P < 0.05; ** P < 0.01; ✝ not calculated due to sample size; OR, odds ratio; CI, confidence interval.  
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Table 2. Reasons for codeine use. 
 Respondents scoring <5 on the 
Severity of Dependence Scale 
(not indicating codeine 
dependence) 
(N = 262) 
Respondents scoring ≧5 on the 
Severity of Dependence Scale 
(indicating codeine 
dependence) 
(N = 54) 
 
 % % OR (95% CI) 
For treatment of pain 91 78** 0.35 (0.16−0.76) 
To help sleep 20 38** 2.57 (1.38−4.81) 
To help relax 19 48** 3.94 (2.13−7.29) 
To feel better when down or 
depressed 
12 44** 5.96 (3.1−11.47) 
To get stoned or intoxicated 10 17 1.82 (0.8−4.13) 
To feel elated or euphoric 10 28** 3.65 (1.77−7.52) 
To stop worrying about a 
problem 
7 33** 6.78 (3.23−14.22) 
To ease withdrawal symptoms 
of other opioids 
2 13** 6.36 (2.05−19.75) 
* P < 0.05; ** P < 0.01; OR, odds ratio; CI, confidence interval.  
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Table 3. Codeine ‘shopping’ of prescription and ‘over-the-counter’ codeine. 
 Respondents scoring <5 on the 
Severity of Dependence Scale 
(not indicating codeine 
dependence) 
(N = 262) 
Respondents scoring ≧5 on the 
Severity of Dependence Scale 
(indicating codeine 
dependence) 
(N = 54) 
 
 % % OR (95% CI) 
Prescription codeine    
Faked or exaggerated 
symptoms to get a 
prescription for codeine 
5 30** 7.46 (3.38−16.48) 
Received prescriptions from 3 
or more prescribers in 6 
months 
5 20** 4.55 (1.95−10.64) 
 
 
‘Over-the-counter’ codeine    
Bought codeine ‘over-the-
counter’ from 3 or more 
pharmacies in 6 months 
31 61** 3.57 (1.95−6.54) 
Refused codeine in a 
pharmacy and then gone to a 
different pharmacy 
6 24** 4.89 (2.2−10.88) 
 
** P < 0.01; OR, odds ratio; CI, confidence interval.  
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Table 4. Sources for seeking help to manage the use of codeine. 
 Respondents scoring <5 on the 
Severity of Dependence Scale 
(not indicating codeine 
dependence) 
(N = 262) 
Respondents scoring ≧5 on the 
Severity of Dependence Scale 
(indicating codeine 
dependence) 
(N = 54) 
 
 % % OR (95% CI) 
On the Internet 6 41** 10.57 (5.03−22.2) 
From a GP 3 19** 8.3 (2−22.90) 
From a pharmacist < 1 2✝ ✝ 
* P < 0.05; ** P < 0.01; ✝ not calculated due to sample size; OR, odds ratio; CI, confidence interval. 
 
 
